MedTrace Logo

Personalized Therapies in Inflammatory Complex Disease

NCT03651518 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-05-20

No results posted yet for this study

Summary

Inflammatory diseases may display atypical features making such patients impossible to classify. Management of these cases in daily practice cannot rely on the results of clinical trials nor on guidelines. DNA and RNA mapping have become major tools to understand and sometimes direct the treatment strategy in oncology. This study aims to test whether a precise analysis of molecular pathways in inflammatory, non classified diseases, can constitute a predictive tool of therapeutic efficiency

Conditions

Interventions

DRUG

Kineret

100 mg, once/day sc 6 months

DRUG

Humira

40 mg/15 days sc 6 months

DRUG

Stelara

45 mg/12 weeks sc, 6 months

DRUG

Cosentyx

300mg sc every week for 1 month, then 300 mg/month sc for 5 months

DRUG

Roactemra

480 mg/perf/4 weeks 6 months

DRUG

Rituximab

2 sessions of 1000 mg at inclusion and 15 days after inclusion

Sponsors & Collaborators

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Selim ARACTINGI, PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-20
Primary Completion
2025-11-20
Completion
2025-11-20

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03651518 on ClinicalTrials.gov